Floatz logo

Moxonidine

Hypertension

Vanderbilt University Medical CenterSmall moleculePhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Hypertension cohort.

Asset / SponsorPhaseRating
VALSARTAN
University of Alabama at Birmingham
Phase 4BBB
Hydrochlorothiazide
University of Kansas Medical Center
Phase 4BBB
AMLODIPINE
Jing Liu
Phase 4BBB
Losartan
Rong Zhang
Phase 4BBB
OLMESARTAN MEDOXOMIL
Virginia Polytechnic Institute and State University
Phase 4BBB

View all 50 →

Same molecule, other indications

Moxonidine is also rated in:

Abdominal ObesityDormant
BB
Indicative ·
68 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
BB
Indicative ·
66 / 100
View asset →
polycystic ovary syndromeDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →